Summary:
Phase 1, Open label, nonrandomized, single dose study to investigate the safety, tolerability, and pharmacokinetics of MRTX849 in Subjects with Mild, Moderate and Severe Renal Impairment
Qualified Participants Must:
• Male or Female
• Age 18 to 75 Years old
• BMI 18 to 40
• Have been diagnosed with kidney disease or have a kidney impairment
• Avaliable for a 8 Day/ 7 Night stay at the Research Center